With regard to the use of progestins in breast cancer, the problem is still under investigation, since progestin therapy can have controversial results in relation to triple-negative (progesterone receptor (PR), estrogen receptor (ER) and HER2 receptor-negative) and receptor-positive breast cancer status. This evidence concerns the gene ESR1 and breast carcinoma.